Background-Unexplained left ventricular hypertrophy (LVH) is considered diagnostic of hypertrophic cardiomyopathy (HCM) but fails to identify all genetically affected individuals. Altered diastolic function has been hypothesized to represent an earlier manifestation of HCM before the development of LVH; however, data regarding the clinical utility of imaging techniques that assess this parameter are limited.
H ypertrophic cardiomyopathy (HCM) is an autosomaldominant disorder characterized by unexplained left ventricular hypertrophy (LVH), abnormalities of diastolic function, and increased risk for sudden death. 1, 2 More than 140 disease-causing mutations have been identified in genes encoding sarcomere proteins, most commonly myosin heavy chain (␤-MHC), cardiac myosin binding protein C, cardiac troponin T, and cardiac troponin I. [3] [4] [5] The echocardiographic finding of LVH not accounted for by other systemic or cardiac disease generally serves as the basis for diagnosing
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HCM. Nevertheless, the presence or absence of LVH is not an infallible diagnostic criterion and the spectrum of hypertrophy is broad, even among individuals with the same mutation. 2, 6 Furthermore, because full expression of the HCM phenotype typically does not occur until adolescence or thereafter, 4, 7, 8 establishing the clinical diagnosis of HCM early in life may be particularly challenging.
Impaired diastolic function is common in patients with overt HCM, 9 but its role in preclinical HCM is less well established. Conventional echocardiographic methods for assessing diastolic function have relied on transmitral Doppler flow patterns and velocities, but there has been no consistent relationship between these indices and left ventricular (LV) end-diastolic pressure, 10, 11 the extent of LVH, the presence or absence of LV outflow tract obstruction, symptoms, or exercise capacity. 9 -13 Doppler tissue imaging (DTI) is a recently validated echocardiographic technique that allows measurement of myocardial velocities in systole and diastole and provides the potential for load-independent assessments of diastolic function. 14, 15 Indeed, studies incorporating DTI have shown a close correlation between early diastolic myocardial (Ea) velocities and LV filling pressures in patients with HCM. 16 Data from a transgenic rabbit model of HCM 17 and preliminary echocardiographic studies on humans 18 suggest that Ea velocities are abnormally low in genotype-positive subjects before the development of LVH. Therefore, we performed a study to assess whether abnormalities of diastolic function may appear before development of LVH and serve as a clinical marker for the presence of genetic mutations in HCM.
Methods

Study Population
Our study population consisted of genotyped individuals from kindreds with HCM caused by ␤-MHC mutations. Genetically affected subjects with LVH (Gϩ/LVHϩ, maximal wall thickness Ͼ12 mm) and without LVH (Gϩ/LVHϪ) were compared with each other and with normal control subjects of similar age (genetically unaffected family members and healthy volunteers). Informed consent was obtained from all participants in accordance with the guidelines of the Institutional Review Board of Brigham and Women's Hospital. Study subjects were assessed by history, physical examination, ECG, and echocardiography. Individuals were excluded if they were found to have coexistent conditions that may contribute to the development of LVH or diastolic abnormalities (eg, systemic hypertension, coronary artery disease, and valvular heart disease).
Echocardiographic Protocol
Echocardiographic studies were performed with an Agilent Sonos 5500 ultrasound system. Standard 2-dimensional images, M-mode, spectral and color Doppler, and Doppler tissue interrogation were performed. A single observer (C.Y.H.) analyzed the echocardiographic data offline, blinded to knowledge of both genotype and control or study subject status. LV septal and posterior wall thickness, cavity dimensions and volumes, mass, and left atrial size were determined from 2-dimensional images according to established criteria. 19, 20 LV ejection fraction (EF) was calculated from LV volumes using the modified Simpson's method. 19 Peak early (E) and late (A) transmitral velocities, E/A ratio, E-wave deceleration time, and isovolumic relaxation time (IVRT) were measured from spectral Doppler displays. 9 Doppler tissue myocardial velocities were measured in systole (Sa) and early diastole (Ea) and with atrial contraction (Aa) at the lateral, septal, inferior, and anterior corners of the mitral annulus. 11, 14 Statistical Analysis ECG findings between the study groups were compared using Fisher's exact test. Multiple group comparisons of echocardiographic parameters among the 3 study groups were made using ANOVA followed by post hoc t testing with Bonferroni correction. PϽ0.05 was considered statistically significant. Univariate and multivariate logistic regressions were used to assess the relative contribution and independence of echocardiographic parameters and age on genotype status. Receiver operating characteristic (ROC) curves were plotted to determine the optimal cutoff values for individual parameters to predict genotype status.
Results
Clinical Characteristics
Subjects were recruited from 5 unrelated HCM kindreds with different ␤-MHC mutations, Gly768Arg (nϭ1), Arg719Trp (nϭ1), Arg663His (nϭ6), Arg652Gly (nϭ6), and Asp906Gly (nϭ22). The clinical characteristics of the study subjects are shown in Table 1 . The mean ages of the Gϩ/LVHϪ (nϭ18) and control (nϭ36) subgroups were not significantly different (24.2Ϯ10.2 years and 25.8Ϯ9.2 years, respectively). All Gϩ/LVHϪ and control subjects were asymptomatic and taking no cardiac medications and had normal standard echocardiographic studies. There were no significant differences in left atrial size, LV wall thickness, diastolic diameter, or LV mass between the Gϩ/LVHϪ subgroup and normal control subjects. There were no statistically significant differences in ECG findings between the Gϩ/LVHϪ subgroup and normal control subjects (Table 2) . Gϩ/LVHϪ individuals were more likely to have ECG abnormalities; however, most (56%) of these changes were nonspecific ST-and T-wave changes. Only 2 of 18 (11%) of Gϩ/LVHϪ individuals had ECG changes previously implicated as potential early signs of disease expression 7 ; both of these individuals had repolarization abnormalities. No Gϩ/LVHϪ individuals had ECG criteria for LVH, pathological Q waves, or abnormal QRS axis.
Gϩ/LVHϩ individuals (nϭ18) were asymptomatic and had well-preserved LV systolic function. This subgroup was found to have significantly greater LV mass and maximal wall thickness than the other 2 groups. Of note, LVEF in both of the genotype (ϩ) subgroups was significantly higher than in the control group. The Gϩ/LVHϩ subgroup had the highest mean EF (75Ϯ5%), significantly greater than the Gϩ/LVHϪ group (mean EF 71Ϯ6%, PϽ0.05) and normal control subjects (mean EF 64Ϯ5%, PϽ0.0001 compared with both genetically affected subgroups). Traditional measures of diastolic function, including E/A ratio, E-wave deceleration time, and IVRT, were not significantly different among the 3 groups with the exception of increased E-wave deceleration time in the Gϩ/LVHϩ subgroup relative to normal control subjects (201Ϯ86 versus 156Ϯ23 ms, respectively, Pϭ0.007).
Doppler Tissue Imaging
Compared with normal control subjects, the 2 subgroups with ␤-MHC mutations had evidence of abnormal diastolic function by Doppler tissue imaging. This was manifested as significantly lower Ea velocities at each individual corner of the mitral annulus (anterior, inferior, lateral, and septal) as well as the averaged Ea velocities from these 4 corners, regardless of the presence or absence of LVH (Table 3) . Ea velocities were highest in the normal control group (13.5 to 18.2 cm/s) and lowest in the Gϩ/LVHϩ group (8.5 to 10.9 cm/s). The velocities of the Gϩ/LVHϪ group were intermediate (11.6 to 15.8 cm/s). At the individual corners of the mitral annulus, the early diastolic velocities were reduced by 13% to 19% in the Gϩ/LVHϪ group compared with normal control subjects (PϽ0.02). Myocardial velocities in systole (Sa) did not differ significantly between the Gϩ/LVHϪ group and normal control subjects but were reduced by 15% to 21% in the Gϩ/LVHϩ group compared with normal control subjects (PϽ0.005) ( Table 3) .
Prediction of Affected Genotype
Despite statistically significant differences in mean Ea velocities, there was considerable overlap between the individual velocities among the 3 groups (Figure 1) . The greatest degree of overlap occurred between the Gϩ/LVHϪ and control groups. In an analysis of these 2 groups, we found an inverse relationship between Ea velocity and age. As a consequence, a higher Ea velocity was associated with affected genotype in younger individuals (Figure 2 ). An averaged Ea velocity of 9.9 cm/s in individuals Ͼ25 years of age predicted an 80% probability of affected genotype but was nearly 100% predictive in those Յ25 years of age.
LVH, Ea velocity, EF, and age were all univariate predictors of affected genotype. In Gϩ/LVHϪ patients, only Ea velocity and LVEF were independently predictive of genetic status after adjusting for age, wall thickness, and left atrial size (Table 4) . ROC curve analysis identified an optimal cutoff value for averaged Ea velocity of Յ13.5 cm/s. This velocity was associated with a sensitivity of 75% and specificity of 86% for predicting affected genotype. The optimal cutoff value of LVEF was Ͼ68%, associated with a sensitivity of 77% and a specificity of 81%. The combination of EF and Ea velocity was the most specific in predicting genetic status. ROC analysis of the combination of EF and averaged Ea velocity identified an optimal cutoff of LVEF Ն68% and averaged Ea velocity Ͻ15 cm/s. This combination yielded a sensitivity of 44% and specificity of 100% in predicting affected genotype. There were no Gϩ/LVHϪ individuals with a combined EF Ͻ68% and averaged Ea velocity Ն15 cm/s and, conversely, no control subjects with an EF Ն68% and averaged Ea velocity Ͻ15 cm/s (Figure 3 ).
Differences Among Individual MHC Mutations
We examined the effect of specific ␤-MHC mutations (Arg663His, nϭ6; Arg652Gly, nϭ6; and Asp906Gly, nϭ22) on echocardiographic parameters in 3 unrelated families. LV mass in hypertrophied individuals was greatest in association with the Arg663His mutation (379.5Ϯ83.7 g) and least with Asp906Gly (192.6Ϯ33.5 g; PϽ0.0001). LVEF in nonhypertrophied family members was significantly higher with the Arg663His mutation versus Asp906Gly (80Ϯ4% versus 69Ϯ4%, Pϭ0.005). There were minor intermutational differences for Ea and Sa velocities among hypertrophied individuals, but no significant differences were found among nonhypertrophied individuals (data not shown).
Discussion
We report that Doppler tissue imaging can detect subtle abnormalities of diastolic function in individuals with hypertrophic cardiomyopathy before the development of both LVH and alterations in more traditional echocardiographic parameters of diastolic function. Nevertheless, the range of Ea velocities is broad. Although our data and those previously reported 18 suggest that diastolic dysfunction may be a primary component of preclinical HCM, determination of Ea velocities alone in individuals of unknown genotype is not sufficiently sensitive to supplant genetic analysis for definitive, independent determination of affected status. Using age-specific cutoffs for Ea velocity and incorporating other parameters, such as LVEF, may improve the predictive accuracy of these clinical markers. Our findings of altered diastolic function in HCM caused by ␤-MHC mutations relate to those reported by Nagueh et al 18 involving patients with a variety of causal mutations, predominantly in the gene encoding cardiac myosin binding protein C. We limited the scope of our investigation to mutations involving ␤-MHC to attempt to minimize biological variation associated with different mutations. It is possible that our results reflect intrinsic differences between ␤-MHC mutations and those involving other components of the sarcomere, although considerable data indicate that diastolic dysfunction is an important component of HCM produced by ␤-MHC mutations. 21, 22 In addition, the mean age of our Gϩ/LVHϪ subgroup was 11 years younger than that of the comparable group in the prior study. 18 Thus, our study population likely represents an earlier stage of disease development, accounting for the higher Ea and Sa velocities described here.
Our data were consistent with previous studies demonstrating that parameters of diastolic function, including Ea velocities, tend to change with age 23 and suggest that age modifies the relationship between the likelihood of affected genetic status and Ea velocity in HCM. Taken as a whole, our findings indicate that abnormalities of diastolic function become more apparent as genetically affected individuals, with or without LVH, age. Because our Gϩ/LVHϪ subjects were younger than our Gϩ/LVHϩ subgroup and Gϩ/LVHϪ subjects in prior studies, 18 we postulate that abnormalities in systolic function may develop later in life than those in diastolic function. We found a substantial degree of overlap of Ea velocities between the Gϩ/LVHϪ group and normal control subjects, corresponding to an intermediate sensitivity and specificity of diastolic tissue Doppler velocities in predicting affected genotype. In contrast, Nagueh et al 18 reported that a lateral Ea Ͻ14 cm/s had 100% sensitivity and 90% specificity for differentiating genotype-positive individuals without LVH from normal control subjects. Applying this criterion to our population would result in the misclassification of two thirds of our Gϩ/LVHϪ individuals as unaffected. To achieve 100% sensitivity in our group, a threshold lateral Ea velocity of Ͻ22 cm/s would be needed and would be associated with a specificity of only 11%.
In this study, we found reduced systolic myocardial velocities in Gϩ/LVHϩ individuals but not in the Gϩ/LVHϪ subgroup. Thus, our results do not support the hypothesis that impaired systolic function is a primary manifestation of HCM, 24, 25 suggesting instead that diastolic abnormalities may be an earlier consequence of sarcomere protein mutations. Nevertheless, the time course of the development of impaired systolic tissue Doppler velocities relative to the onset of LVH is unclear. It is possible that impaired systolic myocardial velocities develop before and contribute to the development of LVH.
We found a statistically significant increase in LVEF in both of the genotype-positive groups compared with normal control subjects. The observation that EF was increased in the Gϩ/LVHϪ group suggests that this finding is not simply the result of a smaller LV cavity size secondary to LVH but may be related to intrinsic physiological changes caused by sarcomere mutations. Although it has been reported that HCM-causing mutations are associated with impaired sarcomere contractility in in vitro studies, 24, 25 other experimental models, particularly those evaluating ␤-MHC mutations, suggest that a hypercontractile state is conferred by sarcomere protein mutations. 26 -28 It is conceivable that this hypercontractility may then serve as the fundamental stimulus for the development of myocyte hypertrophy. Recognizing that the absolute increase in EF was modest, our findings of supranormal LVEF in individuals with ␤-MHC mutations before the development of LVH may support the presence of fundamentally augmented sarcomere function in HCM.
It is intriguing that the combination of a relatively reduced Ea velocity and increased EF was a highly specific marker of affected genetic status in our population, a finding that could assist in the preclinical diagnosis of HCM. In our study, a LVEF Ն68% in association with an Ea velocity Ͻ15 cm/s indicated an affected genotype, whereas an EF Ͻ68% and Ea velocity Ն15 cm indicated unaffected genetic status with 100% specificity. Determining the strength of this association and whether this finding is specific only for ␤-MHC mutations, or occurs with other genetic causes of HCM, warrants additional study. HCM is the most common heritable cardiovascular disease with a prevalence that approaches 1 in 500. 29 These data provide additional evidence that abnormal diastolic function is an inherent component of the pathophysiology of HCM rather than merely a consequence of LVH or impaired systolic function. Documenting diastolic abnormalities as an early sign of disease could ultimately prove to be an important clinical variable to establish diagnosis, monitor progression of cardiomyopathy, and assess response to early intervention.
